Poster: AML-065: Measurable Residual Disease Status and FLT3 Inhibitor Therapy in Patients with FLT3-ITD-Mutated AML Following Allogeneic Hematopoietic Cell Transplantation

MLA

Emily C. Liang, et al. “Poster: AML-065: Measurable Residual Disease Status and FLT3 Inhibitor Therapy in Patients with FLT3-ITD-Mutated AML Following Allogeneic Hematopoietic Cell Transplantation.” Clinical Lymphoma Myeloma and Leukemia, vol. 21, Sept. 2021, p. S210. EBSCOhost, https://doi.org/10.1016/s2152-2650(21)01313-6.

APA

Emily C. Liang, Connie Chen, Rong Lu, Gabriel N. Mannis, & Lori Muffly. (2021). Poster: AML-065: Measurable Residual Disease Status and FLT3 Inhibitor Therapy in Patients with FLT3-ITD-Mutated AML Following Allogeneic Hematopoietic Cell Transplantation. Clinical Lymphoma Myeloma and Leukemia, 21, S210. https://doi.org/10.1016/s2152-2650(21)01313-6

Chicago

Emily C. Liang, Connie Chen, Rong Lu, Gabriel N. Mannis, and Lori Muffly. 2021. “Poster: AML-065: Measurable Residual Disease Status and FLT3 Inhibitor Therapy in Patients with FLT3-ITD-Mutated AML Following Allogeneic Hematopoietic Cell Transplantation.” Clinical Lymphoma Myeloma and Leukemia 21 (September): S210. doi:10.1016/s2152-2650(21)01313-6.